NEWS
Our Latest News
ARCHIMED Successfully Completes Take-private of Esperion Therapeutics
Esperion Therapeutics is a commercial-stage biopharmaceutical company bringing innovative cardiometabolic and rare/orphan disease therapies to market for patients with unmet medical needs.
ARCHIMED top-ranked buyout fund MED I earns 4.5x on the sale of Vita
October
27,
2023
ARCHIMED Publishes White Paper – “Navigating the FHIR Landscape: A Strategic Approach for Healthcare IT Businesses”
September
27,
2023
ARCHIMED’s sale of Polyplus to Sartorius Stedim earns 300x for MED I, an all-time record return for a private equity investment
April
13,
2023
368